Skip to main content

Table 3 Number of cycles and patients with treatment-related adverse events in >20% of patients (N = 24 patients)

From: Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers

 

Grade (number of cycles)

Patients

 

1

2

3

4

Number

%

Alkaline phosphatase increased

6

   

5

21%

Dysphagia

2

2

1

 

5

21%

Dyspnea

5

3

2

 

5

21%

Hypoalbuminemia

3

1

1

 

5

21%

Dehydration

3

5

1

 

7

29%

Fever

8

   

7

29%

Hypokalemia

11

1

4

2

7

29%

Transaminases increased

11

   

7

29%

Hypertriglyceridemia

7

1

1

 

8

33%

Peripheral sensory neuropathy

8

3

  

8

33%

Vomiting

7

1

4

 

8

33%

Anorexia

7

4

  

9

38%

Urinary tract infection

1

6

2

 

9

38%

Diarrhea

8

6

1

 

10

42%

Hyperglycemia

18

6

2

 

10

42%

Hypomagnesemia

23

6

  

10

42%

Mucositis oral

10

10

2

 

11

46%

White blood cell decreased

14

14

29

3

12

50%

Nausea

17

4

3

 

13

54%

Pain

7

   

13

54%

Alopecia

8

12

  

14

58%

Fatigue

14

14

1

 

15

63%

Anemia

21

45

15

 

20

83%

Platelet count decreased

32

26

14

14

20

83%

Neutrophil count decreased

8

19

26

20

21

88%

  1. Toxicities by grade seen in >20% of patients deemed possibly, probably, or definitely related in all patients eligible for toxicity evaluation. Under grade, this is listed as: Total Number of Cycles. Under Patients, this is listed as the: Total Number of Patients for any grade. There were 24 patients who received at least 1 dose of treatment and were part of the toxicity evaluation. A patient may be counted only once for each grade of toxicity but may appear under more than one grade for each toxicity
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us